BRPI1015483A2 - composições de cápsulas biodisponíveis do composto de alfa-(n-sulfonamida)acetamida amorfo - Google Patents

composições de cápsulas biodisponíveis do composto de alfa-(n-sulfonamida)acetamida amorfo

Info

Publication number
BRPI1015483A2
BRPI1015483A2 BRPI1015483A BRPI1015483A BRPI1015483A2 BR PI1015483 A2 BRPI1015483 A2 BR PI1015483A2 BR PI1015483 A BRPI1015483 A BR PI1015483A BR PI1015483 A BRPI1015483 A BR PI1015483A BR PI1015483 A2 BRPI1015483 A2 BR PI1015483A2
Authority
BR
Brazil
Prior art keywords
sulfonamide
capsule compositions
acetamide compound
amorphous alpha
bioavailable
Prior art date
Application number
BRPI1015483A
Other languages
English (en)
Inventor
Christopher P Price
Ismat Ullah
Jaquan Kalani Levons
Krishnaswamy Srinivas Raghavan
Rajesh Babulal Gandhi
Robert Kevin Perrone
Sachin Chandran
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI1015483A2 publication Critical patent/BRPI1015483A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

composições de cápsulas biodisponíveis do composto de alfa-(n-sulfonamida ) acetamida amorfo. a presente inveção refere-se a composições de cápsula farmacêutica contendo o composto ativo (2r)-2-[[(4-clorofenil)sulfonil][[2-flúor-4-(1,2,4-oxadiazol-3-il)fenil]metil]amino]-5,5,5-trifluorpentanamida, e polietileno glicol (peg), vitamina e sucinato de polietileno glicol , polivinilpirrolidona (pvp) ou copovidona (pvp-acetato de polivinil), com ou sem ácido cítrico.
BRPI1015483A 2009-04-14 2010-04-13 composições de cápsulas biodisponíveis do composto de alfa-(n-sulfonamida)acetamida amorfo BRPI1015483A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16906109P 2009-04-14 2009-04-14
PCT/US2010/030862 WO2010120755A1 (en) 2009-04-14 2010-04-13 Bioavailable capsule compositions of amorphous alpha-(n-sulfonamido)acetamide compound

Publications (1)

Publication Number Publication Date
BRPI1015483A2 true BRPI1015483A2 (pt) 2016-04-26

Family

ID=42235859

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015483A BRPI1015483A2 (pt) 2009-04-14 2010-04-13 composições de cápsulas biodisponíveis do composto de alfa-(n-sulfonamida)acetamida amorfo

Country Status (14)

Country Link
US (1) US8252821B2 (pt)
EP (1) EP2419090B1 (pt)
JP (1) JP2012524092A (pt)
KR (1) KR20120022766A (pt)
CN (1) CN102395361A (pt)
AR (1) AR076305A1 (pt)
AU (1) AU2010236602A1 (pt)
BR (1) BRPI1015483A2 (pt)
CA (1) CA2758847A1 (pt)
EA (1) EA201101286A1 (pt)
MX (1) MX2011010514A (pt)
NZ (1) NZ595335A (pt)
TW (1) TW201041609A (pt)
WO (1) WO2010120755A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60232276D1 (de) 2001-12-20 2009-06-18 Bristol Myers Squibb Co Alpha-(n-sulfonamid)acetamidderivate als beta-amyloidinhibitoren
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
WO2011040797A2 (ko) 2009-10-02 2011-04-07 엘지전자 주식회사 하향링크 참조신호의 전송방법 및 장치
ES2565353T3 (es) 2010-12-16 2016-04-04 Borje S. Andersson Formulaciones farmacéuticas de azol para administración parenteral y métodos para la preparación y el uso de las mismas como tratamiento de enfermedades sensibles a los compuestos de azol
PL2701684T3 (pl) 2011-04-28 2018-09-28 Platform Brightworks Two, Ltd. Ulepszone preparaty pozajelitowe lipofilowych środków farmaceutycznych oraz sposoby ich wytwarzania i stosowania
US20130302414A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
CN113473971B (zh) * 2019-02-22 2024-07-02 詹森药业有限公司 药物配制品
CN115884773A (zh) * 2020-08-21 2023-03-31 詹森药业有限公司 药物制剂

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
NZ321293A (en) 1995-11-17 2001-04-27 Warner Lambert Co Sulfonamide inhibitors of matrix metalloproteinases
NZ333825A (en) 1996-07-22 2000-10-27 Monsanto Co Metalloprotease inhibitors particularly MMP-13
WO1998008490A1 (en) * 1996-09-01 1998-03-05 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
CZ20012545A3 (cs) 1999-01-27 2002-04-17 American Cyanamid Company Acetylenické sulfonamidthiolové inhibitory TACE
JP2002537376A (ja) 1999-02-26 2002-11-05 マーク・アンド・カンパニー・インコーポレイテッド 新規スルホンアミドおよびそれらの使用
JP2005506990A (ja) * 2001-10-19 2005-03-10 アイソテクニカ インコーポレーテッド 新規のシクロスポリン類似体のマイクロエマルションプレコンセントレート
DE60232276D1 (de) 2001-12-20 2009-06-18 Bristol Myers Squibb Co Alpha-(n-sulfonamid)acetamidderivate als beta-amyloidinhibitoren
CL2004000647A1 (es) 2003-03-31 2005-02-04 Wyeth Corp Compuestos derivados de heterociclicos de sulfonamida que contienen fluoro y trifluoro alquilo; composicion farmaceutica; kit farmaceutico; procedimiento de preparacion; y su uso como inhibidores de beta amiloides para tratar alzheimer, angiopatia am
NZ547528A (en) 2003-10-29 2008-11-28 Elan Pharm Inc N-substituted benzene sulfonamides
US7163942B2 (en) 2004-04-01 2007-01-16 Pfizer Inc. Sulfonamide compounds for the treatment of neurodegenerative disorders
WO2005105050A1 (en) * 2004-04-28 2005-11-10 Procarrier, Inc. Oral formulation for delivery of poorly absorbed drugs
BRPI0513379A (pt) 2004-07-13 2008-05-06 Hoffmann La Roche derivados de sulfonamida
US7144894B2 (en) 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
WO2006065710A1 (en) * 2004-12-14 2006-06-22 Wyeth Use of a 5-ht6 agonist for the treatment and prevention of neurodegenerative disorders
PE20080109A1 (es) 2006-02-17 2008-04-01 Wyeth Corp N-sulfonilacion selectiva de alcoholes sustituidos con 2-aminotrifluoralquilo
US7687666B2 (en) 2006-02-17 2010-03-30 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
BRPI0708493A2 (pt) * 2006-03-01 2011-05-31 Roskamp Res Llc compostos para inibição da produção de beta-amilóide
WO2008112249A1 (en) 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8084477B2 (en) * 2007-10-31 2011-12-27 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
CN102088855A (zh) 2008-05-08 2011-06-08 百时美施贵宝公司 2-芳基甘氨酰胺衍生物
KR20110133046A (ko) 2009-03-19 2011-12-09 브리스톨-마이어스 스큅 컴퍼니 베타 아밀로이드 펩티드 생성의 억제제로서의 신규 알파-(ｎ-술폰아미도)아세트아미드 화합물
US8044077B2 (en) 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
US20110071199A1 (en) 2009-03-20 2011-03-24 Bristol-Myers Squibb Company Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
TW201043269A (en) 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound

Also Published As

Publication number Publication date
CN102395361A (zh) 2012-03-28
EP2419090B1 (en) 2013-02-13
EA201101286A1 (ru) 2012-04-30
EP2419090A1 (en) 2012-02-22
AR076305A1 (es) 2011-06-01
US20100260837A1 (en) 2010-10-14
AU2010236602A1 (en) 2011-10-13
NZ595335A (en) 2013-03-28
MX2011010514A (es) 2011-11-29
JP2012524092A (ja) 2012-10-11
CA2758847A1 (en) 2010-10-21
KR20120022766A (ko) 2012-03-12
WO2010120755A1 (en) 2010-10-21
US8252821B2 (en) 2012-08-28
TW201041609A (en) 2010-12-01

Similar Documents

Publication Publication Date Title
BRPI1015483A2 (pt) composições de cápsulas biodisponíveis do composto de alfa-(n-sulfonamida)acetamida amorfo
WO2011014850A3 (en) Topical eutectic-based formulations
IL235983B (en) 2-[(4s)-6-(4-chlorophenyl)-1-methyl-8-(methyloxy)-triazolo[3,4-[a[4,1]benzodiazepine-4-yl]-n-ethylacetamide, salts his and pharmaceutical preparations containing them
EA200901319A1 (ru) Композиции для назального введения
PE20091394A1 (es) Un compuesto de alfa-(n-sulfonamido) acetamida con un inhibidor de produccion de peptido beta amiloide
WO2009072007A3 (en) Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2012048854A3 (en) Formulation suitable for stabilizing proteins, which is free of mammalian excipients
WO2008107149A3 (de) Darreichungsform mit erschwertem missbrauch
EA201390783A1 (ru) Биоразлагаемые композиции для доставки лекарственных средств
MX2009007742A (es) Formulaciones farmaceuticas multi-fasicas de farmacos pobremente solubles en agua para una biodisponibilidad oral de variabilidad alimentada/en ayunas reducida y mejorada.
BRPI0820308B8 (pt) composição farmacêutica compreendendo oxi-hidróxido de ferro em alta carga, seus usos e seus processos de preparação, e comprimido
ZA200807778B (en) Reverse-Phase microcapsules for active ingredients, simplified process of manufacture thereof and combined formulations WDG-CS, ZC, EC-SC and CX
WO2011109415A3 (en) Reducing viscosity of pharmaceutical formulations
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
WO2009043049A3 (en) Pharmaceutical formulations
EP3626253A3 (en) Stable formulations of linaclotide
ZA200900929B (en) Microparticles based on an amphiphilic copolymer and on active ingredient(s) with modified release and pharmaceutical formulations containing same
WO2012085284A3 (en) High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts
WO2012161497A3 (ko) 보습능이 우수한 펩타이드 유도체 및 이의 용도
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
WO2011076209A3 (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
WO2010120662A3 (en) Bioavailable compositions of amorphous alpha-(n-sulfonamido)acetamide compound
WO2012147101A3 (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
NZ594561A (en) A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2368 DE 24-05-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.